본문 바로가기
KERD
논문KCI 등재

중심장액맥락망막병증에서 유리체강내 베바시주맙과 애플리버셉트 주입술의 비교

Comparison of Intravitreal Bevacizumab and Aflibercept Injections for Central Serous Chorioretinopathy

이승준|박민수
대한안과학회 (The Korean Ophthalmological Society)|2021.07|대한안과학회지 (Journal of The Korean Ophthalmological Society)|제62권 제7호|pp. 957-962

0

조회

0

다운로드

1

인용

0

참고문헌

키워드

AfliberceptCentral serous chorioretinopathyBevacizumabSubfoveal choroidal thickness
주제분류안과학

초록

목적: 중심장액맥락망막병증 환자에서 유리체강내 베바시주맙 주입술과 애플리버셉트 주입술 간의 치료 효과 차이를 알아보고자 한다. 대상과 방법: 처음 중심장액맥락망막병증으로 진단받고 유리체강내 항혈관내피성장인자 주사를 받은 환자 49명 51안을 대상으로 하여 의무기록을 후향적으로 분석하였다. 항혈관내피성장인자 주사 종류에 따라 유리체강내 베바시주맙을 주입한 군과 애플리버셉트를주입한 군으로 구분하였고, 시술에 대한 반응이 없거나 악화 시 동일한 약제로 반복 치료하였다. 치료 이후 3개월 이상의 추적 관찰을시행하였고, 최대교정시력과 중심맥락막두께 변화, 치료까지 시행된 주사 횟수 및 기간을 분석하였다. 결과: 유리체강내 베바시주맙 주입술과 애플리버셉트 주입술 모두 치료 전후 의미 있는 시력변화(p<0.0001, p=0.001)와 중심맥락막두께 변화를 보였다(p<0.0001, p=0.011). 하지만 주입 약제에 따른 치료 전후 최대교정시력 및 중심맥락막두께 변화량의 차이는 보이지 않았다. 또한 주입 약제에 따른 치료까지 시행된 주사 횟수 및 기간도 차이를 보이지 않았다. 결론: 중심장액맥락망막병증 환자에서 유리체강내 베바시주맙 주입술 또는 애플리버셉트 주입술 모두 중심장액맥락망막병증의 구조적 및 기능적 회복에 효과가 있었으나, 약제의 종류에 따른 기능적 그리고 해부학적 호전의 정도, 치료까지 시행된 주사 횟수 및 기간의 차이는 없었다.

Abstract

Purpose: We examined differences in the treatment effects of intravitreal bevacizumab injections and intravitreal aflibercept injections in patients with central serous chorioretinopathy. Methods: This retrospective analysis included 51 eyes of 49 patients who received intravitreal anti-vascular endothelial growth factor agent injections after initial diagnosis with central serous chorioretinopathy. The patients were divided into two groups: one received an intravitreal bevacizumab injection, and another one received an intravitreal aflibercept injection. Patients with no reaction to treatment or a worsened condition, received repeat treatment with the same therapy. After treatment, patients were monitored for >3 months. Data were collected regarding best- corrected visual acuity (BCVA), subfoveal choroidal thickness, injection number, and treatment duration. Results: Both intravitreal bevacizumab injections and intravitreal aflibercept injections led to significant differences in BCVA (p < 0.0001, p = 0.001) and subfoveal choroidal thickness (p < 0.0001, p = 0.011), compared between before and after treatment. However, no differences between groups were observed in mean change of BCVA or subfoveal choroidal thickness. In addition, there were no differences between groups in injection number and treatment duration. Conclusions: In patients with central serous chorioretinopathy, both intravitreal bevacizumab injections and intravitreal aflibercept injections are effective treatment methods. There were no differences between the two medicines in terms of functional and anatomical recovery, or the injection number and treatment duration.

참고문헌 (38)

  1. Chhablani J, "Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents", Retina, 35, pp.2489~2497 (2015)
  2. Lim SJ, "Intravitreal bevacizumab injection for central serous chorioretinopathy", Retina, 30, pp.100~106 (2010)
  3. Bae SH, "A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy", Am J Ophthalmol, 152, pp.784~792 (2011)
  4. Chung YR, "Twelve-month efficacy of intravitreal bevacizumab injection for chronic, atypical, or recurrent central serous chorioretinopathy", Retina, 39, pp.134~142 (2019)
  5. Schaal KB, "Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy", Eur J Ophthalmol, 19, pp.613~617 (2009)
  6. Artunay O, "Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy : a prospective, controlled clinical study", Curr Eye Res, 35, pp.91~98 (2010)
  7. Inoue M, "Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy", Ophthalmologica, 225, pp.37~40 (2011)
  8. Broadhead GK, "Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy", Graefes Arch Clin Exp Ophthalmol, 253, pp.979~981 (2015)
  9. Pitcher JD 3rd, "A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy : the CONTAIN study", Br J Ophthalmol, 99, pp.848~852 (2015)
  10. Aydin E, "The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy", J Ocul Pharmacol Ther, 29, pp.10~13 (2013)
  11. Seong HK, "Intravitreal bevacizumab to treat acute central serous chorioretinopathy : short-term effect", Ophthalmologica, 223, pp.343~347 (2009)
  12. Torres-Soriano ME, "A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy(case reports)", Graefes Arch Clin Exp Ophthalmol, 246, pp.1235~1239 (2008)
  13. 권의용, "중심장액맥락망막병증 환자에서 유리체강내 베바시주맙 주입술의 치료 효과에 영향을 주는 요인", 대한안과학회지, 55(3), pp.391~395 (2014), 대한안과학회
  14. Carmeliet P, "Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions", Nat Med, 7, pp.575~583 (2001)
  15. Stewart MW, "Aflibercept(VEGF Trap-eye) : the newest anti-VEGF drug", Br J Ophthalmol, 96, pp.1157~1158 (2012)
  16. Binder S, "Loss of reactivity in intravitreal anti-VEGF therapy : tachyphylaxis or tolerance", Br J Ophthalmol, 96, pp.1~2 (2012)
  17. Gasperini JL, "Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation", Br J Ophthalmol, 96, pp.14~20 (2012)
  18. Radke N, "Intravitreal ziv-aflibercept in treatment of naïve chronic central serous chorioretinopathy related choroidal neovascular membrane", Case Rep Ophthalmol Med, 2017, pp.5036248~ (2017)
  19. Nicholson B, "Central serous chorioretinopathy : update on pathophysiology and treatment", Surv Ophthalmol, 58, pp.103~126 (2013)
  20. Yannuzzi LA, "Central serous chorioretinopathy : a personal perspective", Am J Ophthalmol, 149, pp.361~363 (2010)
  21. Manayath GJ, "Central serous chorioretinopathy : current update on management", Oman J Ophthalmol, 11, pp.200~206 (2018)
  22. Kim M, "Intravitreal ranibizumab for acute central serous chorioretinopathy", Ophthalmologica, 229, pp.152~157 (2013)
  23. 박상욱, "Intravitreal Anti-vascular Endothelial Growth Factor versus Observation in Acute Central Serous Chorioretinopathy: One-year Results", Korean Journal of Ophthalmology, 28(4), pp.306~313 (2014), 대한안과학회
  24. Tekin K, "Intravitreal bevacizumab and ranibizumab in the treatment of acute central serous chorioretihopathy : a single center retrospective study", Semin Ophthalmol, 33, pp.265~270 (2018)
  25. 고경민, "급성 중심장액맥락망막병증 환자에서 유리체내베바시주맙 주입술의 유용성", 대한안과학회지, 53(6), pp.781~785 (2012), 대한안과학회[DOI]
  26. Jung BJ, "Chorioretinal response to intravitreal aflibercept injection in acute central serous chorioretinopathy", Int J Ophthalmol, 12, pp.1865~1871 (2019)
  27. Alishiri A, "Intravitreal bevacizumab administration for the treatment of chronic central serous chorioretinopathy", J Curr Ophthalmol, 31, pp.406~410 (2019)
  28. Tekin K, "Intravitreal aflibercept therapy in eyes with chronic central serous chorioretihopathy : short term results", Arch Soc Esp Oftalmol(Engl Ed), 93, pp.315~323 (2018)
  29. Wells JA, "Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema : two-year results from a comparative effectiveness randomized clinical trial", Ophthalmology, 123, pp.1351~1359 (2016)
  30. Heier JS, "Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema : extrapolation of data to clinical practice", JAMA Ophthalmol, 134, pp.95~99 (2016)
  31. Lotfy A, "Efficacy and frequency of intravitreal aflibercept versus bevacizumab for macular edema secondary to central retinal vein occlusion", Retina, 38, pp.1795~1800 (2018)
  32. Noma H, "Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion", Ophthalmology, 116, pp.87~93 (2009)
  33. Funatsu H, "Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema", Ophthalmology, 112, pp.806~816 (2005)
  34. Lim JW, "Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy", Retina, 30, pp.1465~1471 (2010)
  35. Shin MC, "Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy", Retina, 31, pp.1937~1943 (2011)
  36. Bodla MA, "Effects of intravitreal aflibercept in patients with central serous chorioretinopathy", Pak J Ophthalmol, 36, pp.402~407 (2020)
  37. Stewart MW, "Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF", Expert Rev Clin Pharmacol, 7, pp.167~180 (2014)
  38. Hwang H, "Flat irregular pigment epithelium detachment in central serous chorioretinopathy : a form of pachychoroid neovasculopathy", Retina, 40, pp.1724~1733 (2020)

관련 논문AI추천

급성 중심장액맥락망막병증 환자에서 유리체내베바시주맙 주입술의 유용성고경민, 김종우, 김주연, 최문정대한안과학회 · 대한안과학회지2012 · 제53권 제6호중심장액맥락망막병증 환자에서 유리체내 베바시주맙 주입술의 단기효과김형석, 이재흥대한안과학회 · 대한안과학회지2010 · 제51권 제6호중심장액맥락망막병증 환자에서 유리체강내 베바시주맙 주입술의 치료 효과에 영향을 주는 요인권의용대한안과학회 · 대한안과학회지2014 · 제55권 제3호만성 중심장액맥락망막병증에서 국소레이저광응고술과 유리체 내 베바시주맙 주입술의 효과 비교박동근, 윤영빈, 이규원, 최우석대한안과학회 · 대한안과학회지2024 · 제65권 제4호만성 중심장액맥락망막병증에서 절반에너지 광역학치료와베바시주맙 주입술의 12개월간 치료효과 비교김영승, 김형석, 이영훈, 이태곤, 진선영대한안과학회 · 대한안과학회지2013 · 제54권 제10호베바시주맙 안내주입술로 호전된 하층망막박리를 동반한 중심장액맥락망막병증 1예박성표, 신범호, 정재근대한안과학회 · 대한안과학회지2010 · 제51권 제10호

이 간행물의 다른 논문 (19건)

스마트폰 카메라를 이용한 눈꺼풀처짐 환자의 눈꺼풀 깜박임 특성 분석주진호, 주태성, 박인기, 신재호pp. 873-880코-눈물주머니 점막피판을 이용한 코경유눈물주머니코안연결술의 결과김상덕, 정일원pp. 881-8870.03% Tacrolimus 연고의 소아 플릭텐각막염 치료 효과이종수, 조연지, 김재현pp. 888-894쇼그렌증후군 건성안 환자에서 0.1% 싸이클로스포린 A 점안액의 순응도 조사박도희, 윤희수, 윤현정, 윤경철, 진형남pp. 895-903비접촉안압계와 초음파 각막두께측정계를 이용하여 측정한 중심각막두께의 비교 분석박혜연, 신혜영pp. 904-909
원문 보기